Sage Therapeutics(SAGE) - 2024 Q2 - Quarterly Results

Exhibit 99. 1 Sage Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Pipeline and Business Progress Achieved $7.4 million in ZURZUVAE™ (zuranolone) collaboration revenue during the second quarter of 2024 (50% of the net revenues recorded by Biogen), representing 19% growth from the first quarter More than 1,400 prescriptions shipped and delivered during the second quarter of 2024, nearly doubling from the first quarter Dalzanemdor (SAGE-718) topline data from the LIGHTWAVE (Alzheim ...